FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026727008> ?p ?o ?g. }

• W2026727008 abstract "BACKGROUND: High-dose methotrexate (HDMTX)-induced nephrotoxicity is rare and can be prevented with hydration, urine alkalinization, and leucovorin. When hemodialysis is used, rebound in MTX concentrations can occur after stopping dialysis. Carboxypeptidase metabolizes MTX to inactive metabolites and provides an alternative route of elimination, resulting in >98% decrease in MTX concentrations. METHODS: A 62 year-old woman with a history of Mullerian cancer, previously treated with resection and chemotherapy, presented with confusion, leg weakness, and incontinence. MRI of neuraxis revealed leptomeningeal enhancement in the cervicothoracic cord and cauda equina and T2/FLAIR hyperintensity in the cerebral hemispheric sulci. PET-CT showed FDG avidity in the thoracic cord, cauda equina, and right abdominal wall. CSF flow cytometry revealed abnormal mature B cells, concerning for diffuse large B-cell lymphoma. The presumptive diagnosis was neurolymphomatosis. Dexamethasone and spinal irradiation were initiated. Biopsy of the FDG-avid abdominal nodule was considered but it disappeared on repeat imaging. Cycle 1 of HDMTX and rituximab was complicated by pancytopenia. One month later, the patient re-presented with confusion and required a ventriculoperitoneal shunt for acute communicating hydrocephalus. During cycle 2 of HDMTX, she developed acute kidney injury, transaminitis, and worsening mentation, concerning for MTX toxicity. MTX level 21 hours after administration was 410 micromol/L. Hemodialysis and administration of carboxypeptidase resulted in marked improvement of MTX levels, hepatorenal function, and clinical status. CONCLUSIONS: This is an unusual case of neurolymphomatosis in an immunocompromised patient with previous Mullerian cancer. The etiology of MTX toxicity remains unclear although concomitant UTI and sepsis in our patient was likely contributory. Prompt use of carboxypeptidase eliminated MTX and prevented severe hepatic and hematologic toxicity. Carboxypeptidase is now FDA-approved and should be considered in patients with MTX toxicity who do not respond to standard rescue protocols. Use can be cost-limited as treatment of an average patient may exceed $100,000." @default.
• W2026727008 created "2016-06-24" @default.
• W2026727008 creator A5005352195 @default.
• W2026727008 creator A5014329627 @default.
• W2026727008 creator A5014909652 @default.
• W2026727008 creator A5063978336 @default.
• W2026727008 date "2014-11-01" @default.
• W2026727008 modified "2023-09-22" @default.
• W2026727008 title "CN-10 * SHOULD CARBOXYPEPTIDASE BE USED MORE OFTEN SINCE ITS FDA APPROVAL? - A CASE OF SUCCESSFUL METHOTREXATE TOXICITY RESCUE IN A PATIENT WITH NEUROLYMPHOMATOSIS" @default.
• W2026727008 doi "https://doi.org/10.1093/neuonc/nou243.10" @default.
• W2026727008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4218004" @default.
• W2026727008 hasPublicationYear "2014" @default.
• W2026727008 type Work @default.
• W2026727008 sameAs 2026727008 @default.
• W2026727008 citedByCount "1" @default.
• W2026727008 countsByYear W20267270082015 @default.
• W2026727008 crossrefType "journal-article" @default.
• W2026727008 hasAuthorship W2026727008A5005352195 @default.
• W2026727008 hasAuthorship W2026727008A5014329627 @default.
• W2026727008 hasAuthorship W2026727008A5014909652 @default.
• W2026727008 hasAuthorship W2026727008A5063978336 @default.
• W2026727008 hasBestOaLocation W20267270081 @default.
• W2026727008 hasConcept C126322002 @default.
• W2026727008 hasConcept C141071460 @default.
• W2026727008 hasConcept C2778063415 @default.
• W2026727008 hasConcept C2781059491 @default.
• W2026727008 hasConcept C71924100 @default.
• W2026727008 hasConcept C90924648 @default.
• W2026727008 hasConceptScore W2026727008C126322002 @default.
• W2026727008 hasConceptScore W2026727008C141071460 @default.
• W2026727008 hasConceptScore W2026727008C2778063415 @default.
• W2026727008 hasConceptScore W2026727008C2781059491 @default.
• W2026727008 hasConceptScore W2026727008C71924100 @default.
• W2026727008 hasConceptScore W2026727008C90924648 @default.
• W2026727008 hasLocation W20267270081 @default.
• W2026727008 hasLocation W20267270082 @default.
• W2026727008 hasOpenAccess W2026727008 @default.
• W2026727008 hasPrimaryLocation W20267270081 @default.
• W2026727008 hasRelatedWork W1566973639 @default.
• W2026727008 hasRelatedWork W1965859682 @default.
• W2026727008 hasRelatedWork W1976351524 @default.
• W2026727008 hasRelatedWork W1979164402 @default.
• W2026727008 hasRelatedWork W2036790034 @default.
• W2026727008 hasRelatedWork W2058974957 @default.
• W2026727008 hasRelatedWork W2076562876 @default.
• W2026727008 hasRelatedWork W2080632512 @default.
• W2026727008 hasRelatedWork W2132077526 @default.
• W2026727008 hasRelatedWork W2154528512 @default.
• W2026727008 hasRelatedWork W2160850775 @default.
• W2026727008 hasRelatedWork W2233417982 @default.
• W2026727008 hasRelatedWork W2397626759 @default.
• W2026727008 hasRelatedWork W2408507490 @default.
• W2026727008 hasRelatedWork W2408665009 @default.
• W2026727008 hasRelatedWork W2595142150 @default.
• W2026727008 hasRelatedWork W2799909547 @default.
• W2026727008 hasRelatedWork W2960984900 @default.
• W2026727008 hasRelatedWork W3139423025 @default.
• W2026727008 hasRelatedWork W330038959 @default.
• W2026727008 isParatext "false" @default.
• W2026727008 isRetracted "false" @default.
• W2026727008 magId "2026727008" @default.
• W2026727008 workType "article" @default.